Compare Adaptive Biotechnologies Corp (ADPT) vs Zillow Group Inc Class A (ZG) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Zillow Group (ZG) trades at $32.69, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported revenue of $2.58 billion for 2025 with a net income of $23 million, marking a return to profitability after losses in prior years. Recent news is dominated by multiple securities class action lawsuits alleging anticompetitive conduct, creating significant headline risk.

The investment outlook is clouded by legal overhangs despite positive earnings beats and a consensus analyst price target of $57.80 implying substantial upside. Key risks include the outcome of litigation and the sustainability of recent margin improvements. The high P/E ratio of 131.8 suggests growth expectations are already priced in, demanding flawless execution.